Top Regional Bank Companies To Invest In Right Now

NEW YORK (TheStreet) -- Midwest regional Bank stocks on Friday had a very strong showing, as investors cheered stronger-than-expected November employment numbers.

The Dow Jones Industrial Average was up 1.3%, while the S&P 500 added 1.1% and the NASDAQ Composite  rose 0.7% after the Department of Labor announced that the U.S. unemployment rate for November improved to 7.0% from 7.3% in October.  Economists polled by Reuters on average had estimated the unemployment rate would only improve slightly, to 7.2%.

The Labor Department also said the U.S. economy had added 203,000 nonfarm jobs during November, coming in ahead of the consensus estimate of 182,000.

The November unemployment rate is the lowest in five years.  Here's the unemployment picture over the last decade:



The Labor Department also revised revised previous nonfarm job-growth numbers upward, to 174,000 from 153,000 for September and to 204,000 from 200,000 for October.

The KBW Bank Index (I:BKX) rose 1.4% to 67.41, with all 24 index component showing gains.  U.S. Bancorp (USB) of Minneapolis was the leader among large-cap banks, with shares rising 2.7% to close at $39.65.  Other major Midwest players showing strong gains included Fifth Third Bancorp (FITB) of Cincinnati, which was up 2.6% to $20.34, and Huntington Bancshares (HBAN) of Columbus, Ohio, which rose 2.6% to $9.24.

All eyes this week were on the Friday unemployment figure, however, there's been plenty of other good news this week.  The Bureau of Economic Statistics on Thursday made a major upward revision of its estimate for third-quarter U.S. gross domestic product growth to an annual rate of 3.6% from the previous estimate of 2.8%. 

Top 10 Oil Stocks To Invest In 2015: Barclays PLC (II)

Barclays PLC (Barclays) is a global financial services provider engaged in retail banking, credit cards, wholesale banking, investment banking, wealth management and investment management services. The Company�� operations include its overseas offices, subsidiaries and associates. The Company operates in eight segments: UK Retail and Business Banking (UK RBB), Europe Retail and Business Banking (Europe RBB), Africa Retail and Business Banking (Africa RBB), Barclaycard, Barclays Investment Bank, Barclays Corporate Banking, Wealth and Investment Management, and Head Office and Other Operations. Advisors' Opinion:

• [By Todd Sullivan]

  HHC has increased all our ownership percentage through the repurchasing of outstanding warrants.

  From the 13D/A
  On December 31, 2013, certain of the Reporting Persons entered into swaps for the benefit of certain Pershing Square Funds. Under the terms of the swaps, (i) the relevant Pershing Square Funds will be obligated to pay to the bank counterparty any negative price performance of the 5,399,839 notional number of Common Shares subject to the swaps as of the expiration date of such swaps, plus interest rates set forth in the applicable contracts, and (ii) the bank counterparty will be obligated to pay the relevant Pershing Square Funds any positive price performance of the 5,399,839 notional number Common Shares subject to the swaps as of the expiration date of the swaps. During the term of the swaps, cash will be paid by the bank counterparty to the relevant Pershing Square Fund in an amount equal to the amount of notional distributions or dividends paid by the Issuer in respect of such notional number of Common Shares. All balances will be settled in cash. The Pershing Square Funds��counterparties for the swaps include entities related to Citibank, Nomura, Soci茅t茅 G茅n茅rale and UBS. The swaps do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership of any Common Shares that may be referenced in the swap contracts or Common Shares or other securities or financial instruments that may be held from time to time by any counterparty to the contracts.

• [By Holly LaFon]

  Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than original cost. As stated in the current prospectus, the Fund�� Investor Class Share�� annual operating expense ratio (gross) is 1.28%. The Fund�� adviser has contractually agreed to waive a portion of its fee and/or reimburse Fund expenses to limit total annual operating expenses at 1.25%, which is in effect until October 31, 2015. Other share classes may vary. The Fund charges a 2.0% redemption fee on shares redeemed within six months of purchase. For the most recent month-end performance, please call (877)328-9437 or visit the Advisor�� website at www.auxierasset.com. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future.Spring 2014 Market CommentaryAuxier Focus Fund�� Investor Class returned a modest 0.25% for the quarter ended March 31, while Standard and Poor�� 500 Stock Index (S&P) rose 1.81%. The Fund ended the quarter with 70% in U.S. stocks, 16% foreign stocks, 1.7 % bonds and 12.3% cash. Since inception in 1999, the Fund�� equity exposure has averaged 72%. Our stockholdings in the healthcare industry generally gained for the quarter. But many of our multinational and foreign stocks were hurt by the threat of currency repercussions from geopolitical events in Russia and Ukraine. The foreign portion of the Fund is easily the most undervalued. Longer term, we see a very favorable risk/reward potential with our UK and European holdings. Some emerging market companies we follow are the cheapest in over twenty years. In allocating capital, we much prefer the gloom of down to flat markets and the corrective process that tempers exuberance. We remember that one of th

Top Regional Bank Companies To Invest In Right Now: Continental Resources Inc. (CLR)

Continental Resources, Inc. engages in the exploration, development, and production of crude oil and natural gas primarily in the north, south, and east regions of the United States. The company primarily sells its oil and natural gas production to end users, as well as to midstream marketing companies or oil refining companies at the lease. As of December 31, 2011, its estimated proved reserves were 508.4 million barrels of crude oil equivalent, with estimated proved developed reserves of 205.2 million barrels of crude oil equivalent. The company had interests in 3,255 wells and served as the operator of 2,082 of these wells. Continental Resources, Inc. was founded in 1967 and is headquartered in Enid, Oklahoma.

Advisors' Opinion:

• [By Matt DiLallo]

  Continental Resources (NYSE: CLR  ) CEO Harold Hamm has a dream that one day the United States will be energy independent. What's truly remarkable about the dream is that there is enough science and technology that could make it a reality. In fact, according to Hamm and others, the U.S. could be the world's top oil producer by 2017, in addition to being completely energy independent by 2020. Can this really be true?

• [By Victor Selva]

  Competitors such as Sandridge Energy Inc. (SD), Penn Virginia Corp. (PVA), Newfield Exploration Co. (NFX) also have a negative ROE. An alternative could be Cabot Oil &Gas Corp. (COG), Range Resources Corp. (RRC), SM Energy Co. (SM), Pioneer Natural Resources Co. (PXD) or Whiting Petroleum Corp (WLL), Berry Petroleum Co. (BRY), but for investors searching for a higher ratio, Continental Resources Inc. (CLR) will be the best option.

• [By Robert Rapier]

  At the center of this fracking revolution is the Williston Basin in the Bakken shale formation of North America. Below are our favorite companies operating in this area. Continental Resources (CLR) was a pioneer in the Bakken Formation, entering the Bakken in 2003 with a purchase of 300,000 acres. In 2004, Continental completed the first commercially successful well in the North Dakota Bakken that was both horizontally drilled and fractured.

• [By Jay Yao]

  The benefit of being nimble
  $100 billion is about the cumulative market cap of�Pioneer Natural Resources� (NYSE: PXD  ) ,�EOG Resources� (NYSE: EOG  ) , and�Continental Resources� (NYSE: CLR  ) .�$100 billion is also roughly half of what ExxonMobil spent on share buybacks over the past 10 years.�

Top Regional Bank Companies To Invest In Right Now: Kinross Gold Corporation(KGC)

Kinross Gold Corporation, together with its subsidiaries, engages in mining and processing gold ores. It also involves in the exploration and acquisition of gold bearing properties. The company?s gold production and exploration activities are carried out principally in the Americas, Africa, and the Russian Federation. As of December 31, 2010, its proven and probable mineral reserves were 62.4 million ounces of gold, 90.9 million ounces of silver, and 1.4 billion pounds of copper. The company was founded in 1972 and is based in Toronto, Canada.

Advisors' Opinion:

• [By Jim Jubak]

  As sure as April showers bring May flowers, January brings reserve updates from gold mining companies that foreshadow the annual earnings reports that these companies will issue in February. Yamana Gold (AUY) and Randgold Resources (GOLD) initiate the February earnings parade from gold mining companies, with reports on February 2 and 3, respectively. Kinross Gold (KGC) follows on February 12 with Goldcorp (GG) and Barrick Gold (ABX) reporting on February 13. Newmont Mining (NEM) issues its numbers on February 20.

• [By Hebba Investments]

  Even with rising Q2 costs, GG still has lower true all-in costs than many of its larger competitors' Q1FY13 costs. Compared to Q1FY13 numbers of competitors such as Yamana Gold (AUY) (costs just over $1300), Kinross Gold (KGC) (costs above $1350), Silvercrest Mines (SVLC) (costs below $1100), Newmont Gold (NEM) (costs around $1300) Agnico-Eagle (AEM) (costs around $1400) and Barrick Gold (ABX) (costs around $1200).

• [By Itinerant]

  Goldcorp, Newmont (NEM) or Agnico-Eagle use similar definitions. The important element here is the so-called 'sustaining capital expenditure', which is the capital required to sustain existing production levels. The table below is taken from the Agnico-Eagle presentation referenced above and provides a comparison of company-wide AISC for some of the major gold miners, including Goldcorp, Barrick Gold, Newmont Mining, Yamana Gold (AUY), Randgold (GOLD), Kinross (KGC), Agnico-Eagle Mines, Eldorado Gold (EGO), Goldfields and Centerra (CAGDF.PK). The difference between cash costs and AISC is significant. It is also important to note that these AISC are still noticeably below the present spot price for gold.

• [By Selena Maranjian]

  Kinross Gold (NYSE: KGC  ) sank 40%, and yields about 3%. It has some worried, with its rising debt,�and recently negative�free cash flow. Its stock has been setting some multi-year lows�and, while its earnings are in the red, its revenue has been growing�steadily over the past few years. Last year, management committed itself to quality over quantity -- and delayed some mining projects.

Top Regional Bank Companies To Invest In Right Now: Mellanox Technologies Ltd.(MLNX)

Mellanox Technologies, Ltd., a fabless semiconductor company, engages in the design, development, marketing, and sale of interconnect products primarily in North America, Israel, Europe, and Asia. It offers semiconductor interconnect products that facilitate data transmission between servers, communications infrastructure equipment, and storage systems in enterprise data centers, high-performance computing, and embedded systems. The company provides solutions based on InfiniBand, including host channel adapter, switch and gateway ICs, adapter cards, switch and gateway systems, cables, and software. Its products also support the Ethernet standard. The company provides adapters to server, storage, communications infrastructure, and embedded systems OEMs as ICs or standard card form factors with PCI-X or PCI express interfaces; support server operating systems, including Linux, Windows, AIX, HPUX, Solaris, and VxWorks; and InfiniBand switch ICs to server, storage, communicati ons infrastructure, and embedded systems OEMs to create switching equipment. The company offers its products under the Mellanox, BridgeX, ConnectX, InfiniBlast, InfiniBridge, InfiniHost, InfiniPCI, InfiniRISC, PhyX, InfiniScale, and Virtual Protocol Interconnect trademarks in the United States. It primarily serves enterprise data center, high-performance computing, and embedded end-user markets, as well as embedded systems OEMs. The company sells its products directly, as well as through a network of domestic and international sales representatives, and independent distributors. Mellanox Technologies, Ltd. was incorporated in 1999 and is headquartered in Yokneam, Israel.

Advisors' Opinion:

• [By Mani] Shares of Mellanox Technologies, Ltd. (NASDAQ: MLNX) have fallen 54 percent in the last one year. However, the company could see potential upside from the return of hyperscale high performance computing (HPC) buyers driven by Intel's Grantley later next year, more storage market sales required due to flash, and Ethernet switch share gain helped by open source Layer 3 software.

  Mellanox Technologies is a leading supplier of end-to-end InfiniBand and Ethernet interconnect solutions and services for servers and storage. Mellanox interconnect solutions increase data center efficiency by providing the highest throughput and lowest latency, delivering data faster to applications and unlocking system performance capability.

• [By Alex Planes]

  What: Shares of Mellanox Technologies (NASDAQ: MLNX  ) lost nearly 13% of their value today despite beating expectations last night. Analysts at two investment firms are not at all convinced that last night's good news will translate into long-term strength.

Top Regional Bank Companies To Invest In Right Now: Pain Therapeutics Inc (PTIE)

Pain Therapeutics, Inc., incorporated in May 1998, is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company�� lead drug candidate is REMOXY, which is a painkiller. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, the Company leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.

REMOXY

REMOXY is a controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes excipients. It is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. REMOXY�� capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the rapid increases in plasma levels of oxycodone associated with common methods of abuse and misuse. Its formulation also resists delivery by unapproved routes of administration, such as injection, snorting or inhalation.

Metastatic Melanoma

The Company is developing a drug candidate called PTI-188 to treat metastatic melanoma, a form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. In March 2010, the Company announced data from two open-label! , dose-escalating Phase I studies conducted in Israel to assess the safety, pharmacokinetics, dosimetry and anti-tumor activity of PTI-188. During the year ended December 31, 2010, the second study was completed. The technology used in this program was developed at the Albert Einstein College of Medicine (AECOM). It had licensed worldwide commercial rights to this technology from AECOM.

Hemophilia

The Company has a gene transfer program, initially developed at Stanford University, focused at correcting a genetic disorder in which patients are unable to stop bleeding. During 2010, it conducted a variety of pre-clinical studies with this technology. The Company has licensed worldwide commercial rights to the technology used in this program from Poetic Genetics, LLC (Poetic).

Other product candidates

The Company�� alliance with King includes development of three other abuse-resistant opioid product candidates: hydromorphone, hydrocodone and oxymorphone. Its abuse-resistant formulations of hydromorphone and hydrocodone have completed Phase I clinical trials. In January 2011, the Company announced that the Food and Drug Administration (FDA) had accepted its investigational IND, for abuse-resistant oxymorphone.

The Company competes with Roxane Laboratories, Purdue Pharma, King Pharmaceuticals, Inc., Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals.

Advisors' Opinion:

• [By Jessica Alling]

  Elsewhere, Pfizer is evaluating its continued partnership on an experimental oxycodone capsule, Remoxy. The drug is an extended-release formula that is targeted at reducing abuse of the painkiller. After years of setbacks and postponements for FDA approval, Pfizer is weighing its options. Its partners for the drug, Pain Therapeutics (NASDAQ: PTIE  ) and Durect, have both fallen heavily due to the news, with Pain Therapeutics falling more than 50% -- its largest decline ever.